- Incyte is a biopharmaceutical company based in Wilmington, Delaware, focused on oncology and dermatology, with a strong portfolio including Jakafi and a growing pipeline of innovative therapies.
- Incyte reported a total revenue of $5.14 billion for the full year 2025, a 21% increase year-over-year, and provided guidance for 2026 total net product revenue between $4.77 billion and $4.94 billion.
- The company has achieved multiple regulatory approvals and clinical milestones in 2025, advancing several assets from early- to late-stage development, and is expected to have fourteen pivotal clinical trials underway by the end of 2026.
- Incyte's ideal buyers include healthcare providers and institutions focused on oncology and dermatology, as they seek effective treatments for complex conditions, making their innovative product pipeline particularly relevant in the current healthcare landscape.
Incyte's workforce is organized into three primary departments, with a total headcount of 2,620 employees. The largest department, 'Other,' comprises seven employees, while both the 'Education' and 'Operations' departments contribute one employee each. This distribution indicates a lean operational structure, with a significant focus on specialized roles within the organization. The minimal headcount in the top departments suggests a strategic emphasis on efficiency and targeted expertise.
Incyte operates across three key locations, with Wilmington, DE housing the majority of the workforce at two employees. Malvern, PA and Torrance, CA each contribute one employee, reflecting a concentrated presence in Delaware while also maintaining a distributed footprint. The 'Other' category accounts for five additional locations, indicating a diverse geographic distribution that supports operational flexibility and regional engagement.
